Keywords: ph, study, results, show, nuvelo, alfimeprase, well-tolerated

Ph I study results show Nuvelo's alfimeprase is well-tolerated

Article | 15 August 2005

Print This

USA-based Nuvelo has announced clinical data from a Phase I trial of its lead product candidate, alfimeprase, in the Journal ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in